Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million

• Plus Therapeutics posted a Q2 net loss of USD 9 million, or USD 1.31 a share, swinging from net income of USD 5.2 million.
• Operating loss widened to USD 9.1 million from USD 1.5 million, on expanded CNSide commercialization and REYOBIQ Phase 2 spending.
• Grant revenue fell 70.43% to USD 411,000, reflecting lower CPRIT support for REYOBIQ in leptomeningeal metastases.
• Cash, cash equivalents and investments totaled USD 8.6 million at June 30, unchanged from Dec. 31.
• Rebranded as Cerenome effective Aug. 3; continued REYOBIQ trial enrollment, with ReSPECT-GBM data expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141615PRIMZONEFULLFEED9810550) on August 14, 2026, and is solely responsible for the information contained therein.